July 1, 2020; New York, NY
Aquavit has filed a new patent application with the United States Patent and Trademark Office. The patent covers novel methods for treating macular degeneration using its patented microchannel technology.
Age-Related Macular Degeneration (AMD) and Juvenile Macular Dystrophy (JMD) are the number one causes of blindness in older adults and adolescents, respectively. Formulating a compound of biological agents and therapeutic agents such as vitamin B, hydrogels, Hyaluronic acid, botulinum toxins, neuromodulators and delivering these using Aquavit’s proprietary microchannel technology into different ocular tissues can create a novel therapy to treat macular degeneration. This invention (AQA-0622) is the parallel and multimodal site specific microchannel delivery of aforementioned compounds into different structures of the eye such as but not limited to periodic intravitreal, transcorneal, transscleral, and subretinal areas to repair the damage caused by neovascular and neo-neovascular AMD and JMD.
This invention has the potential to be offered in combination of cross-linked and non cross-linked Hydrogel and HA for various purposes and personalization. It is created to repair nervous tissue damage that can restore vision, avoid blindness, and/or slow down the degeneration of the Macula due to injury, ischemic stroke, genetic predisposition, or aging. This invention is designed towards the treatment of Macular degeneration that counts with the largest part visual disorders throughout the lifespan; such as AMD, most frequent in older adults but also prevalent in middle aged adults, and JMD, number one cause of blindness in adolescents and children. Thus, having the potential to impact the route of administration in ophthalmic drug delivery by offering a novel method that has high patient compliance, pain-free approach for the patients.
Current standard of Intravitreal and subretinal injections to treat macular degeneration use syringes that penetrate the eye, having higher risk of damage caused during surgery. Any form of tissue damage can be irreplaceable and cause permanent vision loss. Transcorneal injection with Aquavit’s microchannel technology has the potential to offer a minimally invasive method to treat macular degeneration, offer high patient compliance, reduce risk of damage to the eye, thereby reducing the risk of long term vision loss.
The method of direct injection can be either one individual injection in any of the four anatomical parts - cornea, vitreous cavity, retina, sclera. The timing of any bimodal or multimodal injection delivery can be simultaneous (parallel) or sequential (one at a time on a specific order. This method can become invaluable during times of progressive rapid degeneration leading to blindness. The injections are intended to be applied by a certified Ophthalmologist, Nurse Practitioner, or Physician Assistant.
Aquavit recently filed patent applications pertaining to its drug delivery platforms across immunology, dermatology and nutraceuticals and has been a pioneer in personalized medicine. “Aquavit’s proprietary microchannel delivery technology offers a platform to precisely deliver therapeutic agents in a minimally invasive manner to the different anatomical parts of the eye and reduce the risk of permanent vision loss and also offering higher patient compliance when compared to the current standard of syringes as a route of administration.”, says Sobin Chang, CEO at Aquavit Pharmaceuticals.
Aquavit’s microchannel technology overcomes the existing problems in the ophthalmic drug delivery domain while offering higher patient compliance, reliable and accurate methods to treat macular degeneration when compared to the current commercial offerings. A related technology is currently used in Aquavit’s highly acclaimed AQUAGOLD® fine touch™ device. AQUAGOLD® is currently used by many medical professionals to micro-inject drugs and biologics into the dermal and epidermal skin layers for dermatological applications.
About Aquavit Pharmaceuticals, Inc.
Aquavit Pharmaceuticals, Inc. is a high-tech pharmaceutical company that provides a comprehensive range of innovative pharmaceutical, biotech and medical device technologies. Aquavit Pharmaceuticals, Inc. focuses on personalized medicine to improve patients' health, maximize the efficiency of our medical community, and support the pharmacoeconomics of payers.
Additional information about Aquavit can be found at www.aquavitpharma.com.
To the extent any statements made in this release contain information that is not historical, these statements are essentially forward-looking and are subject to risks and uncertainties, including the difficulty of predicting device approvals, acceptance and demand for new products, new product development and launch, reliance on key strategic alliances, availability of raw materials, availability of additional intellectual property rights, availability of future financing sources, the regulatory environment and other risks the Company may identify from time to time in the future.